Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
True or False: In the KarMMA clinical trial, investigators looked at the use of anti-BCMA CAR-T therapy for relapsed/refractory MM.
RT is an effective bridging option for disease control in high-risk patients with relapsed/refractory LBCL preparing to receive CAR-T therapy.
Fractionated CAR-T Therapy dosing improved _________ in Relapsed/Refractory ALL?
True or False: Radiotherapy can be an effective bridging strategy for disease control in high-risk patients with relapsed/refractory large B-cell lymphoma preparing to receive CAR-T therapy.
True or False: The majority of patients in the phase 2 ZUMA-2 trial with relapsed or refractory MCL benefited from treatment with KTE-X19, an anti-CD19 CAR-T therapy.
_________ is an effective bridging option for disease control in high-risk patients with relapsed or refractory LBCL preparing to receive CAR-T therapy.
True or False: Factors tied to EFS outcomes in patients with B-cell ALL who achieve MRD-negative complete remission after CD19 CAR-T therapy include baseline platelet count, lactate dehydrogenase,…